Serine protease inhibitors interact with IFN-γ through up-regulation of FasR; a novel therapeutic strategy against cancer

Experimental Cell Research

Volumn 330, Issue 2, 2015, Pages 233-239

  Shadrin, Natalia ^a   Shapira, Michal Glickman ^a   Khalfin, Boris ^a,b   Uppalapati, Lakshminarasaiah ^a   Parola, Abraham H ^a,b   Nathan, Ilana ^a,c  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b NEW YORK UNIVERSITY SHANGHAI   (China)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Cancer; Fas; IFN ; Protease inhibitors

Indexed keywords

ELASTASE INHIBITOR; FAS ANTIGEN; GAMMA INTERFERON; MESSENGER RNA; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; TOSYLLYSYL CHLOROMETHYL KETONE; TOSYLPHENYLALANYL CHLOROMETHYL KETONE; FAS LIGAND;

ARTICLE; CANCER THERAPY; CELL DEATH; CELL SURFACE; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; HELA CELL LINE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SENSITIZATION; APOPTOSIS; BIOSYNTHESIS; CELL SURVIVAL; DRUG EFFECTS; DRUG POTENTIATION; GENETICS; HT 29 CELL LINE; METABOLISM; NEOPLASMS; PATHOLOGY; TUMOR CELL LINE; UPREGULATION;

ANTIGENS, CD95; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; FAS LIGAND PROTEIN; HELA CELLS; HT29 CELLS; HUMANS; INTERFERON-GAMMA; NEOPLASMS; RNA, MESSENGER; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; TOSYLLYSINE CHLOROMETHYL KETONE; TOSYLPHENYLALANYL CHLOROMETHYL KETONE; UP-REGULATION;

EID: 84919787248     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.11.005     Document Type: Article

References (27)

1. Wallach D., Varfolomeev E.E., Malinin N.L., Goltsev Y.V., Kovalenko A.V., Boldin M.P. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu. Rev. Immunol. 1999, 17:331-367.
2. Nagata S., Golstein P. The Fas death factor. Science 1995, 267(5203):1449-1456.
3. Nagata S. Early work on the function of CD95, an interview with Shige Nagata. Cell Death Differ. 2004, 11(Suppl 1):S23-S27.
4. Walczak H., Krammer P.H. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp. Cell Res. 2000, 256(1):58-66.
5. Krammer P.H. CD95[U+05F3]s deadly mission in the immune system. Nature 2000, 407(6805):789-795.
6. Alderson M.R., Tough T.W., Davis-Smith T., Braddy S., Falk B., Schooley K.A., et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med. 1995, 181(1):71-77.
7. Dhein J., Walczak H., Bäumler C., Debatin K.M., Krammer P.H. Autocrine T cell suicide mediated by APO-1/(Fas/CD95). Nature 1995, 373(6513):438-441.
8. Ju S.T., Panka D.J., Cui H., Ettinger R., el-Khatib M., Sherr D.H., et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995, 373(6513):444-448.
9. Strasser A., Jost P.J., Nagata S. The many roles of Fas receptor signaling in the immune system. Immunity 2009, 30(2):180-192.
10. Magerus-Chatinet A., Stolzenberg M.C., Lanzarotti N., Neven B., Daussy C., Picard C., et al. Autoimmune lymphoproliferative syndrome caused by a homozygous null Fas ligand (FasLG) mutation. J. Allergy Clin. Immunol. 2013, 131(2):486-490.
11. Gatto D., Brink R. The germinal center reaction. J. Allergy Clin. Immunol. 2010, 126(5):898-907. (quiz 8-9.).
12. de Thonel A., Eriksson J.E. Regulation of death receptors--relevance in cancer therapies. Toxicol. Appl. Pharmacol. 2005, 207(2 Suppl):S123-S132.
13. Martin-Villalba A., Llorens-Bobadilla E., Wollny D. CD95 in cancer: tool or target?. Trends Mol. Med. 2013, 19(6):329-335.
14. Ko Y.C., Chang C.L., Chien H.F., Wu C.H., Lin L.I. Resveratrol enhances the expression of death receptor Fas/CD95 and induces differentiation and apoptosis in anaplastic large-cell lymphoma cells. Cancer Lett. 2011, 309(1):46-53.
15. Hoogwater F.J., Steller E.J., Westendorp B.F., Borel Rinkes I.H., Kranenburg O. CD95 signaling in colorectal cancer. Biochim. Biophys. Acta 2012, 1826(1):189-198.
16. Martini M., Testi M.G., Pasetto M., Picchio M.C., Innamorati G., Mazzocco M., et al. IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine 2010, 28(20):3548-3557.
17. Ni C., Wu P., Zhu X., Ye J., Zhang Z., Chen Z., et al. IFN-gamma selectively exerts pro-apoptotic effects on tumor-initiating label-retaining colon cancer cells. Cancer Lett. 2013, 336(1):174-184.
18. Nathan I., Ben-Valid I., Henzel R., Masalha H., Baram S.N., Dvilansky A., et al. Alterations in membrane lipid dynamics of leukemic cells undergoing growth arrest and differentiation: dependency on the inducing agent. Exp. Cell Res. 1998, 239(2):442-446.
19. Aharon M., Dvilansky A., Shpilberg O., Nathan I. Involvement of proteases in the action of IFN-gamma on WISH cells. J. Interferon Cytokine Res.: Off. J. Int. Soc. Interferon Cytokine Res. 2002, 22(8):847-852.
20. Berman B., Smith B. Trypsin inhibitors inhibit induction by interferon-gamma of HLA-DR antigen expression on human skin cells. Exp. Cell Res. 1989, 183(1):215-228.
21. Smith B., Merlin G., Berman B. Induction of HLA-DR by interferon-gamma requires a trypsin-like protease. J. Interferon Res. 1991, 11(5):275-282.
22. Willemsen L.E., Hoetjes J.P., van Deventer S.J., van Tol E.A. Abrogation of IFN-gamma mediated epithelial barrier disruption by serine protease inhibition. Clin. Exp. Immunol. 2005, 142(2):275-284.
23. Hallak M., Vazana L., Shpilberg O., Levy I., Mazar J., Nathan I. A molecular mechanism for mimosine-induced apoptosis involving oxidative stress and mitochondrial activation. Apoptosis 2008, 13(1):147-155.
24. Zelig U., Kapelushnik J., Moreh R., Mordechai S., Nathan I. Diagnosis of cell death by means of infrared spectroscopy. Biophys. J. 2009, 97(7):2107-2114.
25. Lee Y., Shacter E. Fas aggregation does not correlate with Fas-mediated apoptosis. J. Immunol. 2001, 167(1):82-89.
26. Rossi A., Elia G., Santoro M.G. Activation of the heat shock factor 1 by serine protease inhibitors. An effect associated with nuclear factor-kappaB inhibition. J. Biol. Chem. 1998, 273(26):16446-16452.
27. Xia W., Voellmy R., Spector N.L. Sensitization of tumor cells to Fas killing through overexpression of heat-shock transcription factor 1. J. Cell Physiol. 2000, 183(3):425-431.